Results 51 to 60 of about 77,075 (344)

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Diagnostic significance of pleural fluid pH and pCO2

open access: yesEgyptian Journal of Chest Disease and Tuberculosis, 2015
The diagnosis of pleural effusion is still difficult. The presence of pleural effusion can be confirmed by radiological studies including simple chest radiography, ultrasonography, or computed tomography.
K.E. Sobhey, B.A. Naglaa
doaj   +1 more source

Ovarian Fibroma with Meigs Syndrome associated with Elevated CA125 - A Rare Case [PDF]

open access: yes, 2010
Postmenopausal women with solid adnexal masses, ascites and pleural effusion with elevated CA 125 are highly suggestive for malignant ovarian tumor. However in literature 28 cases Meigs syndrome (Benign ovarian tumor, ascites and right pleural effusion ...
Bafna, UD   +3 more
core  

Massive malignant pleural effusion due to lung adenocarcinoma in 13-year-old boy [PDF]

open access: yes, 2016
A 13-year-old boy with no risk factors for lung cancer presented with a massive left-sided pleural effusion and a mediastinal shift on chest radiography and computed tomography. A chest tube drained bloody pleural fluid with an exudative pattern.
Afghani, R.   +5 more
core   +1 more source

Liquid Metal Nanotransformers for Drug‐Resistant Pan‐Cancer Therapy in Patient‐Derived Organoids

open access: yesAdvanced Science, EarlyView.
Pan‐cancer therapies are severely limited in drug‐resistance patients due to genetic mutations and other factors, resulting in poor therapeutic outcomes and constrained clinical benefit. Liquid metal nanotransformers, a new class of shape‐transformable nanomaterials capable of dramatic morphological changes, offer a promising physical strategy to ...
Xiaojie Yuan   +19 more
wiley   +1 more source

Right Atrial Metastatic Melanoma with Unknown Primaries [PDF]

open access: yes, 2015
A 54-year-old male with history of anemia and rheumatoid arthritis presented with a three-month history of dyspnea on exertion and lower extremity edema. Patient was referred for a transthoracic echocardiogram that revealed a large right atrial mass with
Cowley, Michael   +3 more
core   +4 more sources

Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Engineered microparticles co‐delivering geldanamycin and dual nanobodies induce targeted pyroptosis and block PD‐L1 and CD47 pathways, reprogramming the tumor microenvironment and achieving potent antitumor immunity in lung cancer models with minimal toxicity.
Tianli Hao   +12 more
wiley   +1 more source

Chemoradiotherapy-Integrated Tumor Cell-Derived Microparticles Mediate Tumor Eradication in Malignant Pleural Effusion. [PDF]

open access: yesJ Extracell Vesicles
Highlights: •CR‐MPs functionally simulate concurrent chemoradiotherapy. •CR‐MPs trigger immunogenic ferroptosis and activate innate immunity. •Synergy with immunotherapy drives complete tumor eradication. ABSTRACT Malignant pleural effusion (MPE) portends poor prognosis in advanced cancer.
Zhou M   +18 more
europepmc   +2 more sources

Role of the Neutrophil-Lymphocyte Ratio in the Differential Diagnosis of Exudative Pleural Effusion

open access: yesClinics
OBJECTIVES: Pleural effusion is a common diagnostic and clinical problem. The differential diagnosis of pleural effusion may be difficult and may require several procedures, including invasive ones.
Ulku Aka Akturk   +5 more
doaj   +1 more source

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors [PDF]

open access: yes, 2009
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.
Agarwal, Shruti   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy